Treatment of central nervous system involvement associated with primary Sjögren's syndrome

Current Pharmaceutical Design

Volumn 14, Issue 13, 2008, Pages 1270-1273

  Ozgocmen, Salih ^a,c   Gur, Ali ^b  

^a FIRAT UNIVERSITY   (Turkey)

^b DICLE UNIVERSITY   (Turkey)

^c FIRAT UNIVERSITY   (Turkey)

Author keywords

Central nervous system; Immunosuppresant; Sj gren syndrome; Treatment

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EPRATUZUMAB; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESNA; METHYLPREDNISOLONE; PLACEBO; RITUXIMAB; STEROID; TECHNETIUM 99M; TRICYCLIC ANTIDEPRESSANT AGENT;

ANTICHOLINERGIC EFFECT; ASEPTIC MENINGITIS; BONE MARROW SUPPRESSION; BRAIN VASCULITIS; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DRUG MEGADOSE; HEMIPARESIS; HEMORRHAGIC CYSTITIS; HUMAN; LOW DRUG DOSE; LYMPHOMA; MENINGOENCEPHALITIS; MIGRAINE; MOTOR DYSFUNCTION; MYELITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OPTIC NEURITIS; PLASMAPHERESIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; SEIZURE; SENSORY NEUROPATHY; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SJOEGREN SYNDROME; SPINAL CORD DISEASE; SUBARACHNOID HEMORRHAGE;

EID: 47349125331     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208799316366     Document Type: Review

References (58)

1. Fox RI. Sjogren syndrome. Lancet 2005; 366: 321-31.
2. Niemela RK, Hakala M. Primary Sjogren's syndrome with severe central nervous system disease. Semin Arthritis Rheum 1999; 29: 4-13.
3. Ramus-Casals M, Brito-Zeron P, Font J. The overlap of Sjogren's syndrome with other systemic autoimmune diseases. Semin Arthritis Rheum 2007; 36: 246-55.
4. van Bijstcrveld OP, Kruize AA, Bleys RLAW. Central nervous system mechanisms in Sjogren syndrome. Br J Opthalmol 2003; 87: 128-30.
5. Mori K, Iijima M, Koike H, Hattori N, Tanaka F, Watanabe H, et al. The wide spectrum of clinical manifestations in Sjogren's syndrome-associated neuropathy. Brain 2005; 128(Pt 11): 2518-34.
6. Barendregt PJ, van den Bent MJ, van Raaij-van den Aarssen VJ, van den Meiracker AH, Vecht CJ, van der Heijde GL, et al. Involvement of the peripheral nervous system in primary Sjogren's syndrome. Ann Rheum Dis 2001; 60: 876-81.
7. Delalande S, de Seze J, Fauchais AL, Hachulla, E, Stojkovic T, Ferriby D, et al. Neurologic manifestations in primary Sjogren syndrome: A study of 82 patients. Medicine 2004; 83: 280-91.
8. Govoni M, Padovan M, Rizz N, Trotta F. CNS involvement in primary Sjogren's syndrome: Prevalence, clinical aspects, diagnostic assessment and therapeutic approach. CNS Drugs 2001; 15: 597-607.
9. Stoltze CA, Hanlon DG, Pease GL, Henderson JW. Keratoconjunctivitis sicca and Sjögren's syndrome. Arch Intern Med 1969; 106: 516-22.
10. Kaltreider HB, Talal N. The neuropathy in Sjögren's syndrome. Ann Intern Med 1969; 70: 751-62.
11. Alexander GE, Stevens MB, Provost TT, Alexander EL, Sjögren syndrome: Central nervous system manifestations. Neurology 1981; 31: 1391-6.
12. Alexander EL, Provost TT, Stevens MB, Alexander GE. Neurologic complications of primary Sjögren's syndrome. Medicine 1982; 61: 247-57.
13. Malinow KL, Yannakakis GD, Glusman SM, EdlowDW, Griffin J, Pestronk A, et al. Subacute sensory neuronopathy secondary to dorsal root ganglionitis in primary Sjögren's syndrome. Ann Neurol 1986; 20: 535-7.
14. Molina R, Provost TT, Alexander EL. Peripheral inflammatory vascular disease in Sjögren's syndrome: Association with nervous system complications. Arthritis Rheum 1985; 28: 1341-7.
15. Drosos AA, Andonopoulos AP, Lagos G, Angelopoulos NV, Moutsopoulos HM. Neuropsychiatric abnormalities in primary Sjögren's syndrome. Clin Exp Rheum 1989; 7: 207-9.
16. Hietaharju A, Yli-Kerttula U, Häkkinen V, Frey H. Nervous system manifestation in Sjögren's syndrome. Acta Neurol Scand 1990; 81: 144-52.
17. Spezialetti R, Bluestein HG, Peter JB, Alexander EL. Neuropsychiatric disease in Sjögren's syndrome: Anti-ribosomal P and antineuronal antibodies. Am J Med 1993; 95: 153-60.
18. Moutsopoulos HM, Sarmas JH, Talal N. Is central nervous system involvement a systemic manifestation of primary Sjögren's syndrome. Rheum Dis Clin North Am 1993; 19: 909-12.
19. Tajima Y, Mito Y, Owada Y, Tsukishima E, Moriwaka F, Tashiro K. Neurological manifestations of primary Sjögren's syndrome in Japanese patients. Intern Med 1997; 36: 690-3.
20. Anaya JM, Villa LA, Restrepo L, Molina JF, Mantilla RD, Vargas S. Central nervous system compromise in primary Sjögren syndrome. J Clin Rheumatol 2002; 8: 189-96.
21. Mori K, Koike H, Misu K, Hattori N, Ichimura M, Sobue G. Spinal cord magnetic resonance imaging demonstrates sensory neural involvement and clinical severity in neuropathy associated with Sjogren syndrome. J Neurol Neurosurg Psychiatry 2001; 71: 488-92.
22. Chang CP, Shiau YC, Wang JJ, Ho ST, Kao A. Abnormal regional cerebral blood flow on 99mTc ECD brain SPECT in patients with primary Sjögren's syndrome and normal findings on brain magnetic resonance imaging. Ann Rheum Dis 2002; 61: 774-8.
23. Morgan K, McFarland HF, Pillemer SR. Central nervous system disease in primary Sjögren's syndrome: The role of magnetic resonance imaging. Semin Arthritis Rheum 2004; 34: 623-30.
24. Rogers SJ, Williams CS, Roman GC. Myclopathy in Sjogren's syndrome: Role of immunosuppressants. Drugs 2004; 64: 123-32.
25. Moutaouakil F, El Moutawakkil B, El Otmani H, Gam I, Rafai MA, Slassi I. Aseptic meningoencephalitis in primary Gougerot-Sjogren's syndrome. Rev Neurol 2005; 161: 1225-7.
26. Hirohata M, Yasukawa Y, Ishida Cm Komani K, Yamada M. Reversible cortical lesions in primary Sjogren's syndrome presenting with meningoencephalitis as an initial manifestation. J Neurol Sci 2005; 232: 111-3.
27. Caselli RJ, Scheithauer BW, Bowles CA, Trenerry MR, Meyer FB, Smigielski JS, et al. The treatable dementia of Sjogren's syndrome. Ann Neurol 1991; 30: 98-101.
28. de Seze J, Stojkovic T, Hachulla E, Breteau G, Michon-Pasturel U, Mounier-Vehier F, et al. Myelopathy-Sjögren's syndrome association: analysis of clinical and radiological findings and clinical course. Rev Neurol 2001; 157: 669-78.
29. Williams C, Butler E, Roman G. Treatment of myelopathy in Sjögren syndrome with a combination of prednisone and cyclophosphamide. Arch Neurol 2001; 58: 815-9.
30. Vincent TL, Richardson MP, Mackworth-Young CG, Hawke SH, Venables PJ. Sjogren's syndrome-associated myelopathy: Response to immunosuppressive treatment. Am J Med 2003; 114: 145-8.
31. de Seze J, Delalande S, Fauchais AL, Hachulla E, Stojkovic T, Ferriby D, et al. Myelopathics secondary to Sjogren's syndrome: Treatment with monthly intravenous cyclophosphamide associated with corticosteroids. J Rheumatol 2006; 33: 709-11.
32. Wright RA, O'Duffy JD, Rodriguez M. Improvement of myelopathy in Sjogren's syndrome with chlorambucil and prednisone therapy. Neurology 1999; 52: 386-8.
33. Alexander EL. Neurologic case in Sjogren's syndrome: Mono-nuclear inflammatory vasculopathy affecting central/peripheral nervous system and muscle. Rheum Dis Clin North Am 1993; 19: 869-908.
34. Hermisson M, Klein R, Schmidt F, Weller M, Kuker W. Myelopathy in primary Sjogran's syndrome: Diagnostic and therapeutic aspects. Acta Neurol Scand 2002; 105(6): 450-3.
35. Hawley RJ, Hendricks WT. Treatment of Sjogren syndrome myelopathy with azathioprine and steroids. Arch Neurol 2002; 59(5): 875.
36. Canhao H, Fonseca JE, Rosa A. Inravenous gammaglobulin in the treatment of central nervous system vasculitis associated with Sjogren's syndrome. J Rheumatol 2000; 27: 1102-3.
37. Takahashi Y, Takata T, Hoshino M, Sakurai M, Kanazawa I. Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjogren's syndrome. IV immunoglobulin. Neurology 2003; 60: 503-5.
38. Konttinen YT, Kinnunen E, von Bonsdorff M, Lillqvist P, Immonen I, Bergroth V, et al. Acute transverse myelopathy successfully treated with plasmapheresis and prednisone in a patient with primary Sjogren's syndrome. Arthritis Rheum 1987; 30: 339-44.
39. Gerraty RP, McKelvie PA, Byrne E. Aseptic meningoencephalitis in primary Sjogren's syndrome. Response to plasmapheresis and absence of CNS vasculitis at autopsy. Acta Neurol Scand 1993; 88: 309-11.
40. Yoon KH, Fong KY, Koh DR, Suri R. Central pontine myelinolysis-a rare manifestation of CNS Sjogren's syndrome. Lupus 2000; 9: 471-3.
41. Johnstone B, Pepmueller PH, Vieth AZ, Komatireddy G. Effective treatment of neuropsychological deficits in Sjogren syndrome. Appl Neuropsychol 1996; 3: 122-7.
42. Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjogren's syndrome: A pilot study. Arthritis Rheum 2001; 44: 2371-5.
43. Steinfeld SD, Demols P, Appelboom T. Infliximab in primary Sjogren's syndrome: One-year followup. Arthritis Rheum 2002; 46: 3301-3.
44. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, et al. Inefficacy of infliximab in primary Sjogren's syndrome: Results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum 2004; 50: 1270-6.
45. Caroyer JM, Manto MU, Steinfeld SD. Severe sensory neuronopathy responsive to infliximab in primary Sjogren's syndrome. Neurology 2002; 59:1113-4.
46. Zandbelt MM, de Wilde P, van Damme P, Hoyng CB, van de Putte L, van den Hoogen F. Etanercept in the treatment of patients with primary Sjogren's syndrome: A pilot study. J Rheumatol 2004; 31: 96-101.
47. Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, Baum BJ, et al. Etanercept in Sjögren's syndrome: A twelve-week randomized, double-blind, placebocontrolled pilot clinical trial. Arthritis Rheum 2004; 50: 2240-5.
48. Meijer JM, Pijpe J, Bootsma H, Vissink A, Kallenberg CG. The future of biologic agents in the treatment of Sjögren's syndrome. Clin Rev Allergy Immunol 2007; 32:292-7.
49. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42.
50. Silverman GJ, Weismann S. Rituximab therapy and an autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003; 48: 1484-92
51. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81.
52. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, et al. Rituximab treatment in patients with primary Sjogren's syndrome: An open-label phase II study. Arthritis Rheum 2005; 52: 2740-50.
53. Seror R, Sordet C, Guillevin L, Hachulla E, Mason C, Ittah M, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis 2007; 66: 351-7.
54. Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007; 57: 310-7.
55. Steinfeld SD, Tant L. Burmester GR, Teoh NK, Wegener WA, Goldenberg DM, et al. Epratuzamab (humanised anti-CD22 anti-body) in primary Sjogren's syndrome: An open-label phase I/II study. Arthritis Res Ther 2006; 8: R129.
56. Goertsches R, Serrano-Fernandez P, Moller S, Koczan D, Zettl UK. Multiple sclerosis therapy monitoring based on gene expression. Curr Pharm Des 2006; 12(29): 3761-79.
57. Jaster R, Emmrich J. Molecular characteristics of autoimmune pancreatitis. Curr Pharm Des 2006; 12(29): 3781-6.
58. Wick W, Naumann U, Weller M. Transforming growth factor-beta: A molecular target for the future therapy of glioblastoma. Curr Pharm. Des 2006; 12(3): 341-9.